Diagnostics Digest

In this season opener, we sit down with Krista Ewing, Senior Global Product Manager at Porex Corporation. As a renowned global leader in advanced porous solutions across various industries, including medical devices and writing instruments, it provides high-value solutions for product design challenges related to absorption, diffusion, filtration, and more.Nathan chats with Krista about the journey behind the development of TruFlow, the infamous lateral flow product that emerged in response to the challenges faced during the COVID-19 pandemic. The conversation highlights the critical issues of inconsistency in glass fibre materials used for these tests, exacerbated by the soaring demand for COVID-19 diagnostics. Truflow was conceived as a solution to these challenges, aiming to provide more dependable and uniform materials for lateral flow tests, ultimately enhancing the accuracy and reliability of these crucial diagnostics.Press play to learn about the journey and significance of TruFlow in revolutionising lateral flow testing and the impressive teamwork driving its success.

This is the final episode of our 3-part series with the exciting POC diagnostics start-up, ProtonDx.ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.In this episode, CM Life Science Business Manager, Nathan Sharpe, speaks to the Co-Founder and Chief Technology Officer of ProtonDx, Dr. Nicolas Moser. Nicolas earned an MSc at Imperial College London with distinction and received the Hertha Ayrton Centenary Prize (best MSc project) and the MSc Analogue and Digital Integrated Circuit Design Outstanding Achievement Prize (highest ranking MSc student).In this episode, we cover the future of diagnostics from the perspective of an award-winning scientist and industry innovator. If you would like to learn more about the new possibilities with lab-on-chip, then be sure to give it a listen.

In this next episode of our 3-part series with the exciting POC diagnostics start-up, Nathan sits down with Bob Enk, Chairman & President, and Dr. Jesus Rodriguez Manzano, Chief Scientific Officer for an exclusive chat about the future of diagnostics with ProtonDx.Dr. Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes single-molecule technologies, machine learning applied to healthcare, and clinical diagnostics, with a particular interest in low- and middle-income countries. He is the author of over 90 scientific publications and 14 international patent applications and helped co-found ProtonDx just over 3 years' ago.Bob Enk is Chairman and President at ProtonDx. An experienced investing pioneer and CEO with an alternative mindset and demonstrated history of innovation and growth across financial services and healthcare. After joining the business nearly 2 years ago to take it to the next level in its stratospheric growth, he offers insight into his industry experience interacting with key players and clients, working with strategic partners and major investors, and loads more.From the stimulus for this impressive brand to the reality of using point-of-care to tackle infectious disease in 2023 and beyond. Listen to learn more about new possibilities with lab-on-chip, the vision for developing ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need, and the plan to commercialise this essential testing kit.

In this episode, we begin our 3-part series with the exciting POC diagnostics start-up, ProtonDx.ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.Our conversations started with the co-founder and CEO, Professor Pantelis Georgiou. Pantelis holds the position of Professor of Biomedical Electronics at Imperial College London. He heads the Bio‑inspired Metabolic and Infection Technology Laboratory in the Centre for Bio‑Inspired Technology; a multi‑disciplinary group that invents, develops and demonstrates advanced micro‑devices to meet global challenges in biomedical science and healthcare. His research includes applications of lab‑on‑chip technology for genomics and diagnostics targeted towards infectious disease and cancer.In this episode, CM Life Science Business Manager, Nathan Sharpe, asks Pantelis about the mission that ProtonDx is on: getting molecular testing to the point-of-need. If you are interested in learning more about this ambitious start-up, then be sure to have a listen. 

In this episode of Diagnostics Digest, CM Life Science Business Manager Nathan Sharpe speaks with Kevin Fallon, CEO & Co-Founder of FlexMedical Solutions.Since 2016 FlexMedical has been on an exciting journey, jumping from strength to strength. From significant headcount growth to major investment in both equipment and facilities, the business has become one of the most trusted IVD manufacturers in the world in its short lifespan. Now, they're ready to make the next big move.Our team went to visit FlexMedical at their Scottish HQ, where Nathan caught up with Kevin to discuss the company's exciting plans as one of the world's go-to IVD manufacturers. Find out behind the scenes from the journey to the top, the impact of significant growth, and loads more in this fascinating chat.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.

In this episode, Nathan speaks with Richard Acton, former CSO at Cignpost Diagnostics, about transitioning a company from a COVID testing business to a health and wellness business.Cignpost Diagnostics is a leading health and diagnostics company, operating globally to empower and guide people towards living a healthier life. By combining scientific expertise with a relentless focus on people, Cignpost has quickly evolved to become a global leader in COVID-19 screening and health diagnostics, establishing safe, managed environments across a range of sectors, including elite sports, defence, film and TV production, and financial services.Richard has an extensive history growing and accelerating businesses in the point-of-care market, working on R&D, lab operations, quality and clinical functions and plenty more. With experience gaining certification in the space and working to lead scientific operations for a COVID testing company throughout the pandemic sees Richard share exciting insight and knowledge from his time at Cignpost.If you are interesting in learning about all things POC from the perspective of a company at the forefront of innovation who is well versed in diversification and overcoming challenges to create success, then be sure to have a listen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.

In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS).With over 21,000 members in 74 countries, IBMS is the leading professional body for scientists, support staff and students in the field of biomedical science. For over 100 years, it has been dedicated to the promotion, development and delivery of excellence in biomedical science within all aspects of healthcare, and to providing the highest standards of service to patients and the public.We discuss the NHS response to rapid testing, the importance of the IBMS and its members as an organisation and what's to come during its biggest conference. Until June 2021 David led the NHS England and NHS Improvement Pathology consolidation programme, seeking to deliver efficient, high quality and innovative pathology services across England.Now appointed Chief Executive of the IBMS, as an expert advising on policy, strategy and technology deployment, he shares fascinating insights from his experiences at the helm of the biggest healthcare challenge the world has ever seen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.

In this episode, Eleanor speaks with Delphine Galezowski, Director of Market Development in Europe for Adaptive Biotechnologies.We discuss European market expansion strategies within the diagnostics space, the differences between European market access and other global territories, and insights from her time leading teams at AstraZeneca.Whether you’re in the diagnostics industry, are intrigued by market access strategies, or are wondering how different organisations and regions differ within the market – then be sure to have a listen.In the following episodes my colleagues will be discussing a range of key trends and insights into key topics within the wider diagnostics market, too. So please subscribe to the series to be notified when their episodes become available.If you'd like to get in touch about this episode, would like to be a future podcast guest or want to learn more about CM Life Science's services; then please email me at eleanor.doolin@lifesci-cm.com.